Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada

HIV Clinical Trials

Volumn 12, Issue 2, 2011, Pages 89-103

  Andany, Nisha ^a   Raboud, Janet M ^a,b   Walmsley, Sharon ^a,b   Diong, Christina ^b   Rourke, Sean B ^a,c,d   Rueda, Sergio ^a,c,d   Rachlis, Anita ^a,e   Wobeser, Wendy ^f   MacArthur, Rodger D ^g   Binder, Louise ^h   Rosenes, Ron ^h   Loutfy, Mona R ^a,i,j  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ONTARIO HIV TREATMENT NETWORK   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f KINGSTON GENERAL HOSPITAL   (Canada)

^g WAYNE STATE UNIVERSITY   (United States)

^h Canadian Treatment Action Council   (Canada)

ⁱ WOMEN S COLLEGE HOSPITAL   (Canada)

^j NONE   (Canada)

more..

Author keywords

antiretroviral; ethnicity; gender; HIV; lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; CANADA; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; CANADA; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV SEROPOSITIVITY; HUMANS; LIPODYSTROPHY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX CHARACTERISTICS;

EID: 79955074091     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1202-89     Document Type: Article

References (44)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS.1998;12:F51-58. (Pubitemid 28190689)
3. Karmon SL, Moore RD, Dobs AS, Keruly J, et al. Body shape and composition in HIV-infected women: an urban cohort. HIV Med. 2005;6:245-252. (Pubitemid 41025289)
4. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors.AIDS. 2005;19(suppl 4):S14-S21. (Pubitemid 41668981)
5. Huang JS, Harrity S, Lee D, Becerra K, Santos R, Mathews WC. Body image in women with HIV: a cross-sectional evaluation. AIDS Res Ther. 2006;3:17.
6. Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infec.2003;79:137-141. (Pubitemid 36469620)
7. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001; 28(5):445-449. (Pubitemid 34033195)
8. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32(1):48-56. (Pubitemid 36091484)
9. Visnegarwala F, et al. SMART Study, CPCRA 065: Racial differences in the prevalence of self reported changes in body habitus and their association with body composition measurements in a cohort of HIV +ve patients for the Terry Beirn Community Programs for clinical research on AIDS (CPCRA) and the SMART Team. Presented at: The XV International AIDS Conference; 2004. Poster WePeB5931.
10. Heath KV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a populationbased HIV/AIDS treatment database. AIDS. 2001;15:231-239. (Pubitemid 32142299)
11. Raghavan S, Law M, El-Sadr W, Carr A. Ethnic differences in objective measures of lipodystrophy. Presented at: The XV International AIDS Conference; 2004. Abstract WePeB5939.
12. Galli M, Veglia F, Angarano G, Santambrogio S, et al.Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Synd.2003;34(1):58-61.
13. Jacobsen DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution, of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. HIV/AIDS Clin Infect Dis.2005;40:1837-1845. (Pubitemid 40799956)
14. Loutfy MR, Raboud JR, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS.2007;21(9):1147-1155. (Pubitemid 46763285)
15. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender: differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47(4):441-448. (Pubitemid 351366961)
16. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med.2007;4(2):106-119. (Pubitemid 47248489)
17. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. The Joint United Nations Program on HIV/AIDS and the World Health Organization. http://www.unaids.org/documents/20101123-GlobalReport-em.pdf. Accessed January 21, 2011.
18. Public Health Agency of Canada. Summary: Estimates of HIV Prevalence and Incidence in Canada, 2008. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada.http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/pdf/ estimat08-eng.pdf. Accessed January 21, 2011.
19. The Outcomes Committee for the AIDS Clinical Trials Group (ACTG). Quality of Life Forms: Baseline Body Image Questionnaire - Form QL0720. 1998. https://www.fstrf.org/apps/cfmx/apps/actg/html/QOLForms/index.html. Accessed August 14, 2010.
20. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol.1998;38(11):1003-1009. (Pubitemid 28524446)
21. Hawkins, T. Appearance-related side effects of HIV-1 treatment.AIDS Patient Care STDs. 2006;20(1):6-18.22. (Pubitemid 43172777)
22. Chen D, Misra A, Garg A. Lipodystrophy in Human ImmunodeficiencyVirus- infected patients. J Clin EndocrinolMetab. 2002;87(11):4845-4856.
23. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care. 2007;30(1):113-119.
24. Haugaard SB, Andersen O, Halsall I, Iversen J, Hales CN, Madsbad S. Impaired pro-insulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution. Metab Clin Exp. 2007;56: 939-946. (Pubitemid 46890977)
25. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrionol Metab. 2004;286:E261-E271 (Pubitemid 38140318)
26. Duong M, Petit JM, Martha B, et al. Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials. 2006;7(2):41-47. (Pubitemid 44082686)
27. Tien PC, Cole SR, Masters Williams C, et al. Incidence of lipoatrophy in the women's interagency HIV Study.J Acquir Immune Defic Syndr. 2003;34:461-466. (Pubitemid 37500469)
28. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41(5):590-597.
29. Boufassa F, Dulioust A, Lascaux AS, et al. Lipodystrophy in 685 HIV-1-treated patients: infl uence of antiretroviral treatment and immunovirological response. HIV Clin Trials.2001;2(4):339-345. (Pubitemid 32771531)
30. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
31. Hirsch HH, Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection. 2002;30(5): 293-298.
32. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIVinfected population: it all depends on the definition. HIV Med. 2001;2(3):174-180. (Pubitemid 33114761)
33. Baril JG, Junod P, Leblanc R, et al. HIV-associated lipodystrophy syndrome: a review of clinical aspects. Can J Infect Dis Med Microbiol. 2005;16(4):233-243. (Pubitemid 41367844)
34. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 2002;3(1):49-55. (Pubitemid 34189596)
35. Lichtenstein KA, Ward DJ, Moorman AC, et al; and the HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.AIDS. 2001;15:1389-1398. (Pubitemid 32662290)
36. Forrester JE, Gorbach SL. Fat distribution in relation to drug use, human immunodeficiency virus (HIV) status, and the use of antiretroviral therapies in Hispanic patients with HIV infection. Clin Infect Dis. 2003;37(Suppl 2): S62-S68. (Pubitemid 37102726)
37. Galli M, Ridolfo AL, Adorni F, et al. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.Antivir Ther. 2003;8(4):347-354. (Pubitemid 37101639)
38. Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010;54(2):197-203.
39. Van der Valk M, Gisolf EH, Reiss P, et al; for the Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-855. (Pubitemid 32424388)
40. Ribera E, Paradineiro JC, Curran A, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).HIV Clin Trials. 2008;9(6):407-417.
41. Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy; a substudy from the Antiretroviral Regimen Evaluation Study (ARES).HIV Clin Trials. 2007;8(5):337-344. (Pubitemid 350099566)
42. Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in body fat measured by DEXA in patients taking different formulations of stavudine. HIV Clin Trials.2005;6(6):337-343. (Pubitemid 43336968)
43. Kotler DP, Rosenbaum KB, Wang J, Pierson RN. Alterations in body fat distribution in HIV-infected men and women. In: Program and Abstracts of the 12th World AIDS Conference; June 28 - July 3, 1998; Geneva, Switzerland.Abstract 32173.
44. Tungsiripat M, O'Riordan MA, Storer N, et al. Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials. 2009;10(5): 314-319.